{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:45:24Z","timestamp":1790729124475,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,7,15]],"date-time":"2027-07-15T00:00:00Z","timestamp":1815609600000},"content-version":"am","delay-in-days":348,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ijrobp.2026.04.013","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T16:01:35Z","timestamp":1776873695000},"page":"1480-1491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-5353","authenticated-orcid":false,"given":"Amy J.","family":"Wisdom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra Tafuri","family":"Del Vecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forest M.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Floyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Spranger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl_5","key":"10.1016\/j.ijrobp.2026.04.013_bib0001","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","article-title":"CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014","volume":"19","author":"Ostrom","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0002","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0003","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3171\/2008.4.17536","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0004","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2008.19.4969","article-title":"Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status","volume":"27","author":"Brandes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41571-019-0195-3","article-title":"Immunotherapy for glioblastoma: Quo vadis?","volume":"16","author":"Weller","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0006","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0007","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejca.2014.12.019","article-title":"A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma","volume":"51","author":"Westphal","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0008","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0009","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A randomized trial of bevacizumab for newly diagnosed glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/carcin\/bgu243","article-title":"Glioblastoma stem-like cells: At the root of tumor recurrence and a therapeutic target","volume":"36","author":"Jackson","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0011","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0012","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-022-33099-x","article-title":"Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer","volume":"13","author":"Barger","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0013","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1126\/science.aab0015","article-title":"Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer","volume":"348","author":"Bell","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0014","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ccell.2018.08.003","article-title":"Disruption of the \u03b21L isoform of GABP reverses glioblastoma replicative immortality in a TERT promoter mutation-dependent manner","volume":"34","author":"Mancini","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0015","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nature07385","article-title":"Comprehensive genomic characterization defines human glioblastoma genes and core pathways","volume":"455","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0016","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0018","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0019","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.cell.2022.04.038","article-title":"Glioma progression is shaped by genetic evolution and microenvironment interactions","volume":"185","author":"Varn","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0020","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.cell.2023.12.013","article-title":"Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective","volume":"187","author":"Mathur","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0021","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","article-title":"An integrative model of cellular states, plasticity, and genetics for glioblastoma","volume":"178","author":"Neftel","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1541-7786.MCR-07-0280","article-title":"Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas","volume":"6","author":"Li","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0023","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00401-002-0610-0","article-title":"Expression of extracellular matrix components in a highly infiltrative in vivo glioma model","volume":"105","author":"Mahesparan","year":"2003","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0024","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.1158\/1078-0432.CCR-08-0147","article-title":"Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2","volume":"14","author":"Martens","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0025","first-page":"61","article-title":"Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis","volume":"34","author":"Kijima","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The generation and application of patient-derived xenograft model for cancer research","volume":"50","author":"Jung","year":"2018","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0027","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0028","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","article-title":"Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma","volume":"26","author":"Vaubel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0029","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","article-title":"A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity","volume":"180","author":"Jacob","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/oons\/kvad008","article-title":"Glioblastoma modeling with 3D organoids: Progress and challenges","volume":"2","author":"Wang","year":"2023","journal-title":"Oxf Open Neurosci"},{"issue":"suppl 5","key":"10.1016\/j.ijrobp.2026.04.013_bib0031","doi-asserted-by":"crossref","first-page":"S900","DOI":"10.21037\/tcr.2017.06.19","article-title":"Genetically engineered mouse models for studying radiation biology","volume":"6","author":"Castle","year":"2017","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0032","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/bjc.2016.354","article-title":"Cell of origin of glioma: Biological and clinical implications","volume":"115","author":"Alcantara Llaguno","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0033","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccell.2015.09.007","article-title":"Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes","volume":"28","author":"Alcantara Llaguno","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0034","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1093\/neuonc\/noaf128","article-title":"Polyamine acetylation mediates crosstalk between cancer cells and myeloid cells to promote mesenchymal\/plurimetabolic states in glioblastoma","volume":"27","author":"Rana","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0035","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneumeth.2012.03.016","article-title":"A method for stable transgenesis of radial glia lineage in rat neocortex by piggyBac mediated transposition","volume":"207","author":"Chen","year":"2012","journal-title":"J Neurosci Methods"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0036","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2020.100027","article-title":"In utero cortical electroporation of plasmids in the mouse embryo","volume":"1","author":"Meyer-Dilhet","year":"2020","journal-title":"STAR Protoc"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0037","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/nature21356","article-title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","volume":"543","author":"Turner","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0038","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0039","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0040","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0041","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s43018-022-00510-x","article-title":"Integrative multi-omics networks identify PKC\u03b4 and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy","volume":"4","author":"Migliozzi","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0042","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1158\/0008-5472.CAN-19-0680","article-title":"Radiation-induced DNA damage cooperates with heterozygosity of TP53 and PTEN to generate high-grade gliomas","volume":"79","author":"Todorova","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0043","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1535-7163.MCT-07-0062","article-title":"The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity","volume":"6","author":"Miknyoczki","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jnci\/djw229","article-title":"Rad51 degradation: Role in oncolytic virus-poly(ADP-ribose) polymerase inhibitor combination therapy in glioblastoma","volume":"109","author":"Ning","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0045","unstructured":"ClinicalTrials.gov. A study comparing niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma. Accessed March 10, 2026. https:\/\/clinicaltrials.gov\/study\/NCT06388733."},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0046","doi-asserted-by":"crossref","first-page":"5935","DOI":"10.1158\/0008-5472.CAN-21-0752","article-title":"Elimination of radiation-induced senescence in the brain tumor microenvironment attenuates glioblastoma recurrence","volume":"81","author":"Fletcher-Sananikone","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0047","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s44321-025-00201-x","article-title":"Targeting cIAP2 in a novel senolytic strategy prevents glioblastoma recurrence after radiotherapy","volume":"17","author":"Tomimatsu","year":"2025","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0048","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41467-023-36124-9","article-title":"Cellular senescence in malignant cells promotes tumor progression in mouse and patient glioblastoma","volume":"14","author":"Salam","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0049","doi-asserted-by":"crossref","first-page":"550","DOI":"10.15252\/emmm.201505890","article-title":"MET inhibition overcomes radiation resistance of glioblastoma stem-like cells","volume":"8","author":"De Bacco","year":"2016","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0050","doi-asserted-by":"crossref","DOI":"10.1172\/JCI142158","article-title":"Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models","volume":"131","author":"Deland","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0051","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179395","article-title":"Disruption of ataxia telangiectasia-mutated kinase enhances radiation therapy efficacy in spatially directed diffuse midline glioma models","volume":"135","author":"Mangoli","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0052","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-15-2058","article-title":"FGFR1 induces glioblastoma radioresistance through the PLC\u03b3\/Hif1\u03b1 pathway","volume":"76","author":"Gouaz\u00e9-Andersson","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0053","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3892\/ijo.2014.2432","article-title":"The role of Src family kinases in growth and migration of glioma stem cells","volume":"45","author":"Han","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0054","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.celrep.2019.01.076","article-title":"Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation","volume":"26","author":"Minata","year":"2019","journal-title":"Cell Rep"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0055","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/labinvest.3700482","article-title":"Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: Implications for angiogenesis and glioma cell invasion","volume":"86","author":"Zagzag","year":"2006","journal-title":"Lab Invest"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0056","doi-asserted-by":"crossref","first-page":"83701","DOI":"10.18632\/oncotarget.13295","article-title":"CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study","volume":"7","author":"Yadav","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0057","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14051176","article-title":"Current understanding of hypoxia in glioblastoma multiforme and its response to immunotherapy","volume":"14","author":"Park","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0058","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0059","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1200\/JCO.22.01785","article-title":"Reirradiation for recurrent glioblastoma: What we know and what we do not","volume":"41","author":"Knisely","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1172\/JCI136098","article-title":"N-cadherin upregulation mediates adaptive radioresistance in glioblastoma","volume":"131","author":"Osuka","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0061","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/neuonc\/noac074","article-title":"Targeting adaptive radioresistance in glioblastoma","volume":"24","author":"Osuka","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0062","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nature08712","article-title":"The transcriptional network for mesenchymal transformation of brain tumours","volume":"463","author":"Carro","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0063","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ccr.2006.02.019","article-title":"Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis","volume":"9","author":"Phillips","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0064","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ccr.2013.08.001","article-title":"Mesenchymal differentiation mediated by NF-\u03baB promotes radiation resistance in glioblastoma","volume":"24","author":"Bhat","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0065","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nature11287","article-title":"A restricted cell population propagates glioblastoma growth after chemotherapy","volume":"488","author":"Chen","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0066","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/2001-1326-3-17","article-title":"Clinical significance of epithelial-mesenchymal transition","volume":"3","author":"Steinestel","year":"2014","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0067","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216329","article-title":"Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma","volume":"570","author":"De Martino","year":"2023","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0068","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: Report of Radiation Therapy Oncology Group 93-05 protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0069","article-title":"Study protocol: PreOperative Brain Irradiation in Glioblastoma (POBIG) - A phase I trial","volume":"39","author":"Waqar","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0070","first-page":"194","article-title":"Preoperative stereotactic radiosurgery for glioblastoma","volume":"11","author":"Lehrer","year":"2022","journal-title":"Biology (Basel)."},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0071","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/1078-0432.CCR-24-2974","article-title":"Olaparib, temozolomide, and concomitant radiotherapy for partially resected or biopsy-only glioblastoma first-line treatment: Results from the OLA-TMZ-RTE-01 phase I study","volume":"31","author":"Stefan","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0072","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-49316-8","article-title":"ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma","volume":"15","author":"Laverty","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0073","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj5962","article-title":"Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization","volume":"16","author":"Chen","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0074","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-24-0003","article-title":"DNA-PK inhibition shows differential radiosensitization in orthotopic GBM PDX models based on DDR pathway deficits","volume":"24","author":"Dragojevic","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0075","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aat1719","article-title":"The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models","volume":"4","author":"Durant","year":"2018","journal-title":"Sci Adv"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0076","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41586-019-1912-x","article-title":"VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours","volume":"577","author":"Song","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0077","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0078","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1593\/tlo.12253","article-title":"The changes in MGMT promoter methylation status in initial and recurrent glioblastomas","volume":"5","author":"Park","year":"2012","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0079","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1126\/science.abn7570","article-title":"Mechanism-based design of agents that selectively target drug-resistant glioma","volume":"377","author":"Lin","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.dnarep.2007.09.003","article-title":"Mismatch repair proteins collaborate with methyltransferases in the repair of O(6)-methylguanine","volume":"7","author":"Rye","year":"2008","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0081","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/ng.3590","article-title":"Clonal evolution of glioblastoma under therapy","volume":"48","author":"Wang","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0082","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-06-0127","article-title":"A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy","volume":"66","author":"Hunter","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0083","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0084","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1158\/1078-0432.CCR-08-3012","article-title":"MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance","volume":"15","author":"Yip","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0085","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","article-title":"Mechanisms and therapeutic implications of hypermutation in gliomas","volume":"580","author":"Touat","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0086","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1074\/jbc.RA120.013778","article-title":"Targeting the ABC transporter ABCB5 sensitizes glioblastoma to temozolomide-induced apoptosis through a cell-cycle checkpoint regulation mechanism","volume":"295","author":"Lee","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0087","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-23071-6","article-title":"Mitochondrial ATP fuels ABC transporter-mediated drug efflux in cancer chemoresistance","volume":"12","author":"Giddings","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0088","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100748","article-title":"Lipid peroxidation plays an important role in chemotherapeutic effects of temozolomide and the development of therapy resistance in human glioblastoma","volume":"13","author":"Wu","year":"2020","journal-title":"Transl Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0089","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40263-017-0456-6","article-title":"EGFR as a target for glioblastoma treatment: An unfulfilled promise","volume":"31","author":"Westphal","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0090","doi-asserted-by":"crossref","unstructured":"Ni J, Yang Y, Wang Q, et al. Targeting EGFR in glioblastoma with a novel brain-penetrant small molecule EGFR-TKI. Preprint. Posted online January 9, 2022. bioRxiv 426030. doi:10.1101\/2021.01.09.426030","DOI":"10.1101\/2021.01.09.426030"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0091","unstructured":"ClinicalTrials.gov. A study to evaluate ERAS-801 in patients with recurrent glioblastoma (THUNDERBBOLT-1). Accessed March 10, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05222802."},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0092","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12943-017-0670-3","article-title":"Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development","volume":"16","author":"Zhao","year":"2017","journal-title":"Mol Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0093","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1078-0432.CCR-13-1607","article-title":"Inhibition of DNA double-strand break repair by the dual PI3K\/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma","volume":"20","author":"Gil del Alcazar","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0094","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0095","doi-asserted-by":"crossref","first-page":"33440","DOI":"10.18632\/oncotarget.7961","article-title":"PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0096","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41592-018-0048-5","article-title":"An enhanced CRISPR repressor for targeted mammalian gene regulation","volume":"15","author":"Yeo","year":"2018","journal-title":"Nat Methods"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0097","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12967-017-1128-5","article-title":"Optimized creation of glioblastoma patient derived xenografts for use in preclinical studies","volume":"15","author":"William","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0098","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0099","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0101","first-page":"58","article-title":"Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye","volume":"29","author":"Medawar","year":"1948","journal-title":"Br J Exp Pathol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0102","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ni1328","article-title":"See no evil, hear no evil, do no evil: The lessons of immune privilege","volume":"7","author":"Niederkorn","year":"2006","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0306-4522(92)90347-5","article-title":"The acute inflammatory response to lipopolysaccharide in CNS parenchyma differs from that in other body tissues","volume":"48","author":"Andersson","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0104","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature14432","article-title":"Structural and functional features of central nervous system lymphatic vessels","volume":"523","author":"Louveau","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0105","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adu2910","article-title":"The meninges host a distinct compartment of regulatory T cells that preserves brain homeostasis","volume":"10","author":"Marin-Rodero","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0106","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1084\/jem.184.5.1737","article-title":"Microglia induce CD4 T lymphocyte final effector function and death","volume":"184","author":"Ford","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0107","doi-asserted-by":"crossref","first-page":"20918","DOI":"10.1073\/pnas.0911509106","article-title":"Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells","volume":"106","author":"Gottfried-Blackmore","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0108","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0736-5748(99)00020-9","article-title":"Microglia only weakly present glioma antigen to cytotoxic T cells","volume":"17","author":"Fl\u00fcgel","year":"1999","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0109","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41586-025-08633-8","article-title":"Programs, origins and immunomodulatory functions of myeloid cells in glioma","volume":"640","author":"Miller","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0110","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1158\/0008-5472.CAN-16-0144","article-title":"CCL2 produced by the glioma microenvironment is essential for the recruitment of regulatory T cells and myeloid-derived suppressor cells","volume":"76","author":"Chang","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0111","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.3337","article-title":"CSF-1R inhibition alters macrophage polarization and blocks glioma progression","volume":"19","author":"Pyonteck","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0112","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ccell.2017.07.006","article-title":"Macrophage polarization contributes to glioblastoma eradication by combination immunovirotherapy and immune checkpoint blockade","volume":"32","author":"Saha","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0113","doi-asserted-by":"crossref","first-page":"6514","DOI":"10.1158\/1078-0432.CCR-21-1392","article-title":"Tumor cell IDO enhances immune suppression and decreases survival independent of tryptophan metabolism in glioblastoma","volume":"27","author":"Zhai","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0114","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","article-title":"A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets","volume":"3","author":"Wang","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0115","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0116","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0117","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T cells in recurrent glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0118","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adf4726","article-title":"Architects of immunity: How dendritic cells shape CD8+ T cell fate in cancer","volume":"10","author":"Bhandarkar","year":"2025","journal-title":"Sci Immunol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2326-6066.CIR-22-0098","article-title":"The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive antitumor immunity in the brain","volume":"11","author":"Bowman-Kirigin","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/neuonc\/noac138","article-title":"Dysfunctional dendritic cells limit antigen-specific T cell response in glioma","volume":"25","author":"Friedrich","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0121","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17704-5","article-title":"Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types","volume":"11","author":"Khalsa","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0122","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67411-w","article-title":"GL261 luciferase-expressing cells elicit an anti-tumor immune response: An evaluation of murine glioma models","volume":"10","author":"Sanchez","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0123","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41416-018-0258-8","article-title":"Harnessing the immune system in glioblastoma","volume":"119","author":"Brown","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0124","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0125","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","article-title":"Transgenic expression of IL15 improves antiglioma activity of IL13R\u03b12-CAR T cells but results in antigen loss variants","volume":"5","author":"Krenciute","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0126","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26940-2","article-title":"Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma","volume":"12","author":"Lee","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0127","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0128","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: A phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0129","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: A phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ijrobp.2026.04.013_bib0130","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.cell.2025.12.055","article-title":"Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial","volume":"189","author":"Meylan","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0131","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41586-023-06036-1","article-title":"Glioblastoma remodelling of human neural circuits decreases survival","volume":"617","author":"Krishna","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0132","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.cell.2023.02.002","article-title":"Cancer neuroscience: State of the field, emerging directions","volume":"186","author":"Winkler","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ijrobp.2026.04.013_bib0133","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41586-019-1564-x","article-title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","volume":"573","author":"Venkataramani","year":"2019","journal-title":"Nature"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626005870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626005870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T23:17:39Z","timestamp":1785971859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626005870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":133,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0360301626005870"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.013","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms, Microenvironments, and Models: Understanding Therapeutic Resistance in Glioblastoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}